Streetbeat News

Products Services

ENVB

Enveric Biosciences has been granted Patent No. 11,707,441 by the U.S. Patent and Trademark Office. The patent covers EB-373, a new chemical entity psilocin prodrug being developed by Enveric for the treatment of anxiety disorder.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 12:05 pm

BMY

Cellares, a cell therapy manufacturing organization, announced that Bristol Myers Squibb (BMY) has joined its Technology Adoption Partnership (TAP) program. BMY will use Cellares' automated manufacturing platform, the Cell Shuttle, for a proof-of-concept transfer process for one of its CAR-T cell therapies. The TAP program allows cell therapy developers to adopt Cellares' automated manufacturing technology for their products. BMY aims to evaluate the automated manufacturing process and confirm the Cell Shuttle as a cost-efficient and scalable manufacturing solution for cell therapies.

Portfolio Pulse from Happy Mohamed

August 28, 2023 | 12:04 pm

BNGO

Bionano Genomics' Chinese OEM partner, A-smart Medtech, has received Reagent Class I registrations from China's National Medical Products Administration for Bionano's DNA extraction kit and labeling products.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 12:03 pm

FCEL

XOM

FuelCell Energy, Inc. (NASDAQ:FCEL) and ExxonMobil Technology and Engineering Company (EMTEC) have extended their joint development agreement for carbon capture technology through March 31, 2024. The extension will allow further development related to manufacturing scale-up and work towards advancing the carbonate fuel cell technology for carbon capture applications. A final investment decision on a potential demonstration project is expected later this year.

Portfolio Pulse from Happy Mohamed

August 28, 2023 | 12:03 pm

CATX

Perspective Therapeutics is set to present clinical and preclinical data at the 36th Annual Congress of the European Association of Nuclear Medicine. The company's stock, CATX, may be mentioned in the article.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 12:02 pm

LTRN

Lantern Pharma has announced a significant enhancement in the power and capabilities of its RADR platform, aimed at improving the drug development process for immune checkpoint inhibitors.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 12:02 pm

ALUR

Allurion has announced that nine of its scientific presentations have been accepted for the upcoming 26th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 12:01 pm

VRSK

Verisk Analytics Inc (NASDAQ:VRSK) has entered the Egypt health insurance market through a deal with AXA Life & Health Reinsurance Solutions. Verisk will provide its Health Risk Rating Tool and Ratings Engine to automate health insurance underwriting based on pre-existing medical conditions of AXA's customers. The tool will be marketed as AXA's Intelligent Medical Acceptance Tool (IMPACT).

Portfolio Pulse from Shivani Kumaresan

August 28, 2023 | 11:50 am

SRPT

Sarepta Therapeutics has invested in Lexeo Therapeutics' Adeno-associated Virus Gene Therapy Programs. The terms of the deal were not disclosed. The companies will explore the development of novel gene therapy candidates for cardiovascular diseases.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 11:39 am

FSR

Fisker Inc (NYSE:FSR) has expanded into three new European markets - Belgium, the Netherlands, and Switzerland. The company plans to establish retail locations and service centers in these regions, with deliveries starting by the end of September. Fisker also released information on the Fisker Alaska pickup truck, which will be built in the U.S. and has an estimated base price of $45,400. The company reported Q2 FY23 sales of $825,000, missing the analyst consensus of $20.40 million, but beating the EPS loss estimate.

Portfolio Pulse from Lekha Gupta

August 28, 2023 | 11:28 am